Merck Beats Q2 Earnings Estimates, Raises Full-Year Guidance

Merck's second-quarter earnings report exceeded expectations, with the company posting adjusted earnings of a loss of $0.13 per share and revenue of $16.6 billion, beating forecasts by $190 million or 1.16%. The strong results were driven by continued strength in oncology, vaccines, respiratory treatments, and animal health.

The company's non-GAAP gross margin was 81.1%, down 1.1 percentage points due to higher inventory reserves. Operating expenses climbed to $12.6 billion, including a large acquisition charge related to Terns Pharmaceuticals. Merck raised its full-year guidance, predicting revenue of $66.3 billion to $67.3 billion and adjusted EPS of $2.66 to $2.76.

Chief Executive Rob Davis emphasized the company's diversified portfolio and growth opportunities beyond KEYTRUDA, which will face patent pressure in the future. He stated that Merck is 'substantially stronger, more diversified, and better positioned for sustainable growth' than five years ago.